MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/15/2025 11:45 PDT] MediciNova, Inc. (NASDAQ:MNOV), Up By 100% ($1.27) From $1.27 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/11/2025 07:28 PDT] MNOV Expected to Trade Up After Bullish Patterns Develop
• [04/07/2025 10:29 PDT] MediciNova, Inc. (NASDAQ:MNOV), Down By 100% ($1.34) From $1.34 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/04/2025 07:38 PDT] MNOV Expected to Trade Down After Bearish Patterns Develop